NCT02718066 - Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

September 30, 2023

Study Completion Date

September 30, 2023

Conditions

MelanomaRenal Cell CarcinomaNon-Small Cell Lung Cancer

Interventions

DRUG

HBI-8000 in combination with nivolumab

"Phase 1b: HBI-8000, orally, twice a week, dose escalation 20mg, 30mg, 40mg; in combination with nivolumab 240mg intravenous infusion every 2 weeks.~Phase 2: HBI-8000 MTD or 40mg; in combination with nivolumab in accordance with the manufacturer package insert and institution's prescribing practice."

Trial Locations (6)

21702

[Site 13] Frederick Memorial Hospital d/b/a James M Stockman Cancer Institute, Frederick

33612

[Site 09] H. Lee Moffitt Cancer Center and Research Institute, Inc., Tampa

34952

[Site 01] Hematology - Oncology Associates of the Treasure Coast, Port Saint Lucie

77030

[Site 12] University of Texas M.D. Anderson Cancer Center - Investigational Cancer Therapeutics, Houston

85054

[Site 02] Mayo Clinic Arizona, Phoenix

92037

[Site 11] University of California, San Diego Medical Center, La Jolla

All Listed Sponsors

lead

HUYABIO International, LLC.

INDUSTRY